--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

American scientists have made huge strides towards finding a cure for HIV using pioneering ‘gene editing’ techniques. After years of research, the team from Temple University in Pennsylvania used their technique to eliminate the virus from human cells by ‘snipping’ it out.

The successful experiments took place in the lab, but the team is confident the treatment could be trialled on humans within three years. In a 2014 study, the researchers successfully managed to remove the HIV DNA from normal human cells. This time around, they used the same technology to remove it from infected T-cells, which play a major role in the immune system, in a more accurate simulation of how the virus would be treated inside patients’ bodies.

During their studies, the team drew blood from people living with HIV. Their T-cells were cultured in the lab, and then treated with the Crispr/Cas9 gene editing system, in which a targeted protein uses enzymes to remove genetic sequences (in this case, HIV DNA) from cells. Their results definitively proved it is possible to eliminate the virus and prevent it from re-infecting cells using this treatment.

Gene editing is an important field for medical researchers, but there are fears that

the process could have negative effects beyond the boundaries of the cells, resulting in further health problems. However, using highly-detailed genome sequencing to analyse the treated cells, the scientists found they continued to grow and function normally, and didn’t appear to be suffering from any side-effects.

According to Kamel Khalili, the leader of the study, “The findings are important on multiple levels.They demonstrate the effectiveness of our gene editing system in eliminating HIV from the DNA of T-cells and, by introducing mutations into the viral genome, permanently inactivating viral replication.”

Khalili added that the study has “huge potential,” and  “Based on the findings we should be entering into clinical trials within three years.” A paper detailing their study has now been published in the high-profile Scientific Reports journal.

Vennila is one of BioTecNika's Online Editors. When she is not posting news articles and jobs on the website, she can be found gardening or running off to far flung places for the next adventure, armed with a good book and mosquito repellant. Stalk her on her social networks to see what she does next.